ibrx-20260804 FALSE 0001326110 0001326110 2026-08-04 2026-08-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2026 ImmunityBio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37507 43-1979754 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 3530 John Hopkins Court San Diego , California 92121 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (844) 696-5235 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐ Section 2 – Financial Information Item 2.02     Results of Operations and Financial Condition. On August 4, 2026, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the three and six months ended June 30, 2026, and its financial position as of June 30, 2026. The full text of the Company’s press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filings of the Company made under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing. Section 9 – Financial Statements and Exhibits. Item 9.01     Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description of Exhibit 99.1** Press release dated August 4, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). _______________ **    Furnished herewith. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: August 4, 2026 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer

ImmunityBio announced Q2 2026 financial results and a business update on August 4, 2026, providing investors with an overview of the company's operational and financial position as of June 30, 2026.

On August 4, 2026, ImmunityBio, Inc. provided a business update along with its financial results for the three and six months ended June 30, 2026. The report outlines the company's financial position as of June 30, 2026, likely detailing revenue, expenses, and net income or losses. This update is critical for investors and stakeholders to assess the company's performance during the fiscal period. The filing includes a press release as Exhibit 99.1, which contains the detailed financial statements and operational insights necessary for informed decision-making regarding the company's future.

ImmunityBio, Inc.

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means